How many insider trades does FilingIQ track for VRXA?

FilingIQ tracks 3 Form 4 insider transactions for VRXA (Veraxa Biotech AG), covering filings from Aug 31, 2026 onwards. 3 of those are dated within the last 90 days.

Are VRXA insiders net buyers or net sellers?

Across the full Form 4 history for VRXA, 3 transactions (100%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does VRXA insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.

What sector is VRXA in?

Veraxa Biotech AG (VRXA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $185.24M.

VRXA insider trading

NasdaqGM Healthcare

Veraxa Biotech AG: insider trade history from SEC Form 4 filings.

Total Form 4 trades

Last 90 days

Buys / sells

100% / 0%

Market cap

$185.24M

About Veraxa Biotech AG

VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company utilizes proprietary payloads and genetic code expansion technology to engineer and manufacture homogeneous, stable bioconjugates with defined drug-to-antibody ratios. It also licenses technology platforms to support the development of new therapeutic strategies. The company serves professional clients in the healthcare sector, including those in drug development, biologicals, diagnostics, instrumentation, and partners with research organizations and business partners in the life sciences industry. The company was founded in 2021 and is based in Heidelberg, Germany.

Company website: www.veraxa.com

VRXA insider activity at a glance

FilingIQ tracks 3 insider transactions for VRXA in filings since Aug 31, 2026. The most recent transaction is dated Sep 10, 2026.

Across the full history, 3 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on VRXA insider trades is 62.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live VRXA trades on FilingIQ Raw filings on SEC EDGAR

Latest VRXA Form 4 filings

Antz Christoph Rudiger Chief Executive Officer

P Aug 31, 2026

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 752

UNITED THERAPEUTICS Corp

BLLN 165

BillionToOne, Inc.

TMO 130

THERMO FISHER SCIENTIFIC INC.

Attovia Therapeutics, Inc.

TEM 109

Tempus AI, Inc.

CORT 98

CORCEPT THERAPEUTICS INC

Frequently asked

How many insider trades does FilingIQ track for VRXA?: FilingIQ tracks 3 Form 4 insider transactions for VRXA (Veraxa Biotech AG), covering filings from Aug 31, 2026 onwards. 3 of those are dated within the last 90 days.
Are VRXA insiders net buyers or net sellers?: Across the full Form 4 history for VRXA, 3 transactions (100%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does VRXA insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
What sector is VRXA in?: Veraxa Biotech AG (VRXA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $185.24M.

Methodology & sources

Every VRXA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.